HALOZYME THERAPEUTICS, INC.
HALO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HALO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HALO
Halozyme Therapeutics is a biopharmaceutical company that uses its proprietary ENHANZE® drug delivery technology to partner with other pharmaceutical companies, generating revenue primarily through royalties on partnered products.
Key risk: High debt burden
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 2 catalysts for HALOZYME THERAPEUTICS, INC..
Halozyme Therapeutics is a biopharmaceutical company that uses its proprietary ENHANZE® drug delivery technology to partner with other pharmaceutical companies, generating revenue primarily through royalties on partnered products.
- Reported record total revenues of $1,397 million in 2025, a 38% increase from $1,015 million in 2024 [sec · filed 2026-03-23].
- Revenues from royalties were $868 million in 2025, a 52% increase from $571 million in 2024, driven by sales of DARZALEX SC, Phesgo, and VYVGART Hytrulo [sec · filed 2026-03-23].
- As of 2026-06-30, the company had cash & equivalents of $164.0M, total revenue of $481.0M, net income of $229.9M, shareholders' equity of $332.7M, and total debt of $2,146.7M [latest reported financials].
- In Q2 CY2026, revenue was $481 million, up 47.7% year-over-year, with non-GAAP profit of $2.28 per share, 25.5% above analysts' consensus [news · published 2026-08-11].
- The company filed a patent infringement lawsuit against Merck and obtained a preliminary injunction in Germany to stop the distribution of Keytruda SC, which it believes infringes its MDASE™ SC delivery technology patents [sec · filed 2026-03-23].
What works
- Strong and growing royalty revenue from multiple partnered products (DARZALEX SC, Phesgo, VYVGART Hytrulo) provides a diversified and recurring income stream [sec · filed 2026-03-23].
- The company's proprietary ENHANZE® drug delivery technology is protected by a portfolio of patents, which it is actively enforcing through litigation, as seen with the preliminary injunction against Merck's Keytruda SC [sec · filed 2026-03-23].
- Management has deep experience in commercializing pharmaceutical products, including launching new drugs and leading large organizations, which supports execution of the company's strategy [sec · filed 2026-03-23].
What to weigh
- The company carries a high level of total debt ($2,146.7M as of 2026-06-30), which could create financial risk and limit flexibility [latest reported financials].
- Revenue growth is heavily dependent on the commercial success of a limited number of partnered products, making the company vulnerable to sales declines or patent expiries of those products [sec · filed 2026-03-23].
- The company faces ongoing litigation and patent challenges, such as the lawsuit against Merck, which could result in significant legal costs or adverse outcomes that affect its intellectual property position [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
Record total revenues in 2025 driven by royalty growth
“Reported record total revenues of $1,397 million, which increased 38% from $1,015 million in 2024.”
SEC filings · March 23, 2026
Patent enforcement action against Merck for Keytruda SC
“Defense of our MDASE™ SC delivery technology intellectual property by filing a patent infringement lawsuit against Merck and obtaining a preliminary injunction from a German court ordering Merk to refrain from distributing and offering Keytruda SC in Germany.”
SEC filings · March 23, 2026
Q2 CY2026 revenue and profit beat analyst estimates
“The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.”
News · August 11, 2026
Catalyst timeline
- 2030-03-01 · Phase3_Topline — Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet — Topline data from this Phase 3 study will provide key safety and efficacy data for the product under investigation.
- 2030-11-30 · Patent_Expiry · TLANDO — Patent/Exclusivity Expiry: TLANDO — Expiration of patent or exclusivity for TLANDO may open the market to generic competition, potentially reducing related revenue.
Risks & what to watch (4)›
Key risks
- High debt burden — Total debt of $2,146.7M as of 2026-06-30 may constrain financial flexibility and increase vulnerability to interest rate changes [latest reported financials].
- Concentration on partnered products — Revenue is heavily reliant on a few key partnered products (e.g., DARZALEX SC, Phesgo); loss of market share or patent expiry could materially impact revenue [sec · filed 2026-03-23].
- Patent litigation outcomes — Ongoing patent litigation with Merck and potential challenges to the ENHANZE® patent portfolio could result in adverse judgments or loss of exclusivity [sec · filed 2026-03-23].
- Execution of new partnerships — Future growth depends on securing new collaboration agreements; failure to do so could limit revenue diversification and growth prospects [sec_mda · as of 2026-02-17].
What to watch
- Progress of the Phase 3 topline results for the open-label, multiple-dose, 52-week study plus 24-month long-term safety extension, expected around 2030-03-01 [upcoming catalysts].
- Patent/Exclusivity expiry for TLANDO on 2030-11-30, which could impact related revenue streams [upcoming catalysts].
- Outcome of the patent infringement lawsuit against Merck regarding Keytruda SC, which could affect the company's intellectual property position and future royalty income [sec · filed 2026-03-23].
- Quarterly earnings reports and any updates to full-year revenue guidance, as the company has consistently beaten analyst estimates in recent quarters [news · published 2026-08-11].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run HALOZYME THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HALOZYME THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 16.96 · 3% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~1279d
0 buys · 53 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
630
Total value held
$7.49B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,265,053 | $857.3M |
| vanguard capital management llc | 10,542,436 | $681.4M |
| vanguard portfolio management llc | 5,249,206 | $339.3M |
| state street corp | 4,937,854 | $319.1M |
| bank of america corp /de/ | 2,913,109 | $188.3M |
| morgan stanley | 2,562,309 | $165.6M |
| william blair investment management, llc | 2,525,975 | $163.3M |
| geode capital management, llc | 2,505,786 | $162.0M |
| janus henderson group plc | 2,467,316 | $159.5M |
| snyder capital management l p | 2,323,077 | $150.1M |
Showing top 10 of 630 institutional holders of HALOZYME THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 15.7%
- Days to cover
- 10.3
- Shares short
- 14,381,741
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HALO short interestGovernance
Frequently asked questions
What is the AI investment thesis for HALOZYME THERAPEUTICS, INC.?
Halozyme Therapeutics is a biopharmaceutical company that uses its proprietary ENHANZE® drug delivery technology to partner with other pharmaceutical companies, generating revenue primarily through royalties on partnered products.
What is HALOZYME THERAPEUTICS, INC.'s lead drug candidate?
HALOZYME THERAPEUTICS, INC.'s most advanced tracked candidate is xyosted (Approved).
What is HALOZYME THERAPEUTICS, INC.'s next catalyst?
HALOZYME THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet" — expected March 1, 2030.
Who is the CEO of HALOZYME THERAPEUTICS, INC.?
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. is the chief executive officer of HALOZYME THERAPEUTICS, INC. (HALO).
Where is HALOZYME THERAPEUTICS, INC. headquartered?
HALOZYME THERAPEUTICS, INC. (HALO) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.